FDA OKs Immunicon's rare cell collection tube
This article was originally published in Clinica
Cancer diagnostic firm Immunicon has received US FDA clearance to market a blood collection tube that preserves circulating tumour cells. The New York company believes its CellSave preservative tube to be the only one of its kind currently available. A spokesperson for the firm told Clinica: "To our knowledge there is no such 'draw tube' on the market today for preserving circulating tumour cells, which have potential medical utility in the management of cancer patients."
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.